Cognitive outcome measures for tracking Alzheimer's disease in Down syndrome.

4区 医学 Q3 Medicine
Victoria Fleming, Christy L Hom, Isabel C H Clare, Shemaya L Hurd-Thomas, Sharon Krinsky-McHale, Benjamin Handen, Sigan L Hartley
{"title":"Cognitive outcome measures for tracking Alzheimer's disease in Down syndrome.","authors":"Victoria Fleming, Christy L Hom, Isabel C H Clare, Shemaya L Hurd-Thomas, Sharon Krinsky-McHale, Benjamin Handen, Sigan L Hartley","doi":"10.1016/bs.irrdd.2022.05.006","DOIUrl":null,"url":null,"abstract":"<p><p>Down syndrome (DS) is now viewed as a genetic type of Alzheimer's disease (AD), given the near-universal presence of AD pathology in middle adulthood and the elevated risk for developing clinical AD in DS. As the field of DS prepares for AD clinical intervention trials, there is a strong need to identify cognitive measures that are specific and sensitive to the transition from being cognitively stable to the prodromal (e.g., Mild Cognitive Impairment-Down syndrome) and clinical AD (e.g., Dementia) stages of the disease in DS. It is also important to determine cognitive measures that map onto biomarkers of early AD pathology during the transition from the preclinical to the prodromal stage of the disease, as this transition period is likely to be targeted and tracked in AD clinical trials. The present chapter discusses the current state of research on cognitive measures that could be used to screen/select study participants and as potential outcome measures in future AD clinical trials with adults with DS. In this chapter, we also identify key challenges that need to be overcome and questions that need to be addressed by the DS field as it prepares for AD clinical trials in the coming years.</p>","PeriodicalId":44571,"journal":{"name":"International Review of Research in Developmental Disabilities","volume":"62 ","pages":"227-263"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10312212/pdf/nihms-1910069.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Review of Research in Developmental Disabilities","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/bs.irrdd.2022.05.006","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/7/21 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Down syndrome (DS) is now viewed as a genetic type of Alzheimer's disease (AD), given the near-universal presence of AD pathology in middle adulthood and the elevated risk for developing clinical AD in DS. As the field of DS prepares for AD clinical intervention trials, there is a strong need to identify cognitive measures that are specific and sensitive to the transition from being cognitively stable to the prodromal (e.g., Mild Cognitive Impairment-Down syndrome) and clinical AD (e.g., Dementia) stages of the disease in DS. It is also important to determine cognitive measures that map onto biomarkers of early AD pathology during the transition from the preclinical to the prodromal stage of the disease, as this transition period is likely to be targeted and tracked in AD clinical trials. The present chapter discusses the current state of research on cognitive measures that could be used to screen/select study participants and as potential outcome measures in future AD clinical trials with adults with DS. In this chapter, we also identify key challenges that need to be overcome and questions that need to be addressed by the DS field as it prepares for AD clinical trials in the coming years.

Abstract Image

追踪唐氏综合症患者阿尔茨海默病的认知结果测量。
唐氏综合征(DS)现在被视为阿尔茨海默病(AD)的一种遗传类型,因为AD病理学在成年中期几乎普遍存在,并且在DS中发展为临床AD的风险较高。随着DS领域为AD临床干预试验做准备,强烈需要确定对DS患者从认知稳定到疾病的前驱期(例如轻度认知障碍唐氏综合征)和临床AD(例如痴呆)阶段的转变具有特异性和敏感性的认知测量。在疾病从临床前阶段过渡到前驱阶段期间,确定映射到早期AD病理学生物标志物的认知测量也很重要,因为这一过渡期可能是AD临床试验的目标和跟踪期。本章讨论了认知测量的研究现状,这些测量可用于筛选/选择研究参与者,并作为未来成人DS AD临床试验的潜在结果测量。在本章中,我们还确定了DS领域在为未来几年的AD临床试验做准备时需要克服的关键挑战和需要解决的问题。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.10
自引率
0.00%
发文量
12
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信